Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CGTX | US
0.02
1.59%
Healthcare
Biotechnology
30/06/2024
24/04/2026
1.28
1.25
1.31
1.24
Cognition Therapeutics Inc. a clinical-stage biopharmaceutical company engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812 an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase New York.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
85.2%1 month
188.6%3 months
124.2%6 months
105.5%-
-
0.86
0.03
0.02
-0.44
-
-
-58.61M
51.37M
51.37M
-
-
-
-
-108.31
1.04
1.91
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.47
Range1M
0.78
Range3M
0.92
Rel. volume
0.39
Price X volume
883.12K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CDIO | CDIO | Biotechnology | 1.82 | 55.69M | 0.00% | n/a | 28.31% |
| OKYO Pharma Limited | OKYO | Biotechnology | 1.61 | 54.48M | 1.26% | n/a | -107.88% |
| Rani Therapeutics Holdings Inc. Class A Common Stock | RANI | Biotechnology | 0.9389 | 54.33M | 2.56% | n/a | 1243.32% |
| LYRA THERAPEUTICS INC | LYRA | Biotechnology | 0.8 | 52.37M | 10.34% | n/a | 118.63% |
| 22nd Century Group Inc | XXII | Biotechnology | 1.66 | 52.18M | -2.92% | n/a | -1072.15% |
| Gain Therapeutics Inc. Common Stock | GANX | Biotechnology | 1.97 | 50.30M | 4.23% | n/a | 6.85% |
| PEPG | PEPG | Biotechnology | 1.54 | 50.19M | -3.14% | n/a | 12.52% |
| Tenax Therapeutics Inc | TENX | Biotechnology | 14.3 | 48.75M | 2.36% | n/a | 3.14% |
| Clene Nanomedicine Inc | CLNN | Biotechnology | 5.91 | 47.06M | -3.90% | n/a | -6472.02% |
| Minerva Neurosciences Inc | NERV | Biotechnology | 6.575 | 45.98M | -3.73% | n/a | -194.60% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 21.77 | 33.16M | -2.81% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.44 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.86 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 124.23 | 72.80 | Riskier |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 51.37M | 3.66B | Emerging |